Articles
10 June 2009
Vol. 2 No. 14: Immunomodulatory drugs: the foundation for treating hematological malignancies Amsterdam, 15 June 2006
https://doi.org/10.4081/hmr.v2i14.510

Prolonging time to progression and survival in relapsed/refractory multiple myeloma

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
207
Views
405
Downloads

Authors

Pieter Sonneveld
support@pagepress.org
Each year, over 16,500 new cases of multiple myeloma (MM) are diagnosed in the USA alone, making it the second most common type of haematological malignancy after non-Hodgkin’s lymphoma.1 Current treatment options for MM are non-curative, and the 5-year survival rate for all patients with MM has improved only slightly over the last 20−25 years, from 25% to 32%.

Altmetrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite



Prolonging time to progression and survival in relapsed/refractory multiple myeloma. (2009). Hematology Meeting Reports (formerly Haematologica Reports), 2(14). https://doi.org/10.4081/hmr.v2i14.510